Log in to search using one of your social media accounts:

 

New Guidelines Issued on HIV Treatment During Pregnancy (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Tenofovir-emtricitabine should not be a first treatment choice for women with HIV who are pregnant, according to new patient-centered … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 12, 2017 Category: Primary Care Source Type: news

Maraviroc-containing Regimens Appear Safe for HIV PrEP in Women Maraviroc-containing Regimens Appear Safe for HIV PrEP in Women
Maraviroc-containing regimens appear to be safe and well tolerated, compared with tenofovir-emtricitabine (TDF-FTC), for preventing HIV infection in women, according to results from a phase 2 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 22, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Aurobindo Pharma gets USFDA nod for anti-HIV drug
Aurobindo Pharma has received tentative approval from the USFDA for dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets, used for the treatment of HIV, in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 21, 2017 Category: Pharmaceuticals Source Type: news

Mylan rolls out HIV treatment medicine in Canada
Mylan launched three generic medications to treat HIV in Canada. The pharmaceutical company, which is based in the Netherlands but run out of its corporate offices in Canonsburg, said it had received Health Canada approval for these generic drugs: emtricitabine/tenofovir disoproxil fumarate 200 mg/300 mg, a generic alternative to Truvada efavirenz/emtricitabin e/tenofovir disoproxil fumarate 600 mg, 200 mg, and 300 mg, a generic alternative to Atripla tenofovir disoproxil 300 mg, a generic alternative… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 10, 2017 Category: American Health Authors: Paul J. Gough Source Type: news

Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada
Mylan now offers generic alternatives to Truvada®, Atripla® and Viread® to patients in Canada1 HERTFORDSHIRE, England and PITTSBURGH and TORONTO, Aug. 10, 2017 -- (Healthcare Sales & Marketing Network) -- Mylan Pharmaceuticals ULC, a subsid... Biopharmaceuticals, Generics, Product Launch Mylan, Truvada, Atripla, Viread (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 10, 2017 Category: Pharmaceuticals Source Type: news

Gilead Announces U.S. FDA Priority Review Designation for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug. 10, 2017-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the company ’s New Drug Application (NDA) for an... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - August 10, 2017 Category: Drugs & Pharmacology Source Type: news

Mylan launches new HIV treatment in India
Mylan NV said it is the first company to offer an innovative, reduced-dose HIV treatment in India. Mylan (Nasdaq:MYL) subsidiary Mylan Pharmaceuticals Private Limited has received marketing authorization from the Drug Controller General of India for its antiretroviral drug Avonza. The fixed-dose combination comprised of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets is recommen ded by the World Health Organization as an alternative first-line regimen for people being treated for… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 9, 2017 Category: Pharmaceuticals Authors: Patty Tascarella Source Type: news

Lower Risk of Adverse Birth Outcomes With Tenofovir-emtricitabine-efavirenz Lower Risk of Adverse Birth Outcomes With Tenofovir-emtricitabine-efavirenz
Exposure of infants, from conception, to the antiretroviral combination of tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TFC-FTC-EFV) is associated with a lower risk of adverse birth outcomes, compared with exposure to other antiretroviral regimens, according to data from Botswana.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Bone Risk with Tenofovir: How to Handle? (CME/CE)
(MedPage Today) -- Studies examine role of common HIV drug (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 28, 2017 Category: Primary Care Source Type: news

Janssen Receives Positive CHMP Opinion for SYMTUZA ™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV
- Proven efficacy and durability of darunavir combined with the improved renal laboratory and bone mineral density profile of emtricitabine/tenofovir alafenamide as compared to emtricitabine/tenofovir disoproxil fumarate into one single tablet (Source: Johnson and Johnson)
Source: Johnson and Johnson - July 21, 2017 Category: Pharmaceuticals Source Type: news

Tenofovir to Prevent Mother-to-child Transmission of HBV Tenofovir to Prevent Mother-to-child Transmission of HBV
Is tenofovir safe and tolerable for both the mother and fetus when administered to pregnant women with chronic HBV infection?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 20, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

How Common Are STIs?
Discussion Of the 30 different microbes which can be transmitted by sexual contact, 8 have the greatest incidence of transmitting disease. Four are curable (Chlamydia, Gonorrhea, Syphilis and Trichomoniasis) and 4 are incurable at present (Hepatitis B, Herpes simplex virus (HSV), Human immunodeficiency virus (HIV) and Human papillomavirus (HPV)). Sexually transmitted infections (STIs) are important as they can cause: Increased rates of acquisition of other STIs (ie HSV and syphilis increase the rate of HIV infection acquisition) Pelvic inflammatory disease and infertility Stillbirth and neonatal death Neonatal morbidity i...
Source: PediatricEducation.org - July 17, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

HCC Drops Beyond Five Years of Entecavir/Tenofovir Tx for Hep B
Older age, lower platelets at baseline and year five, liver stiffness ≥ 12 kPa linked to HCC development (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 21, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Infections, Oncology, Pharmacy, Journal, Source Type: news

Efficacy and Safety After Switching From TDF to TAF in HIV Efficacy and Safety After Switching From TDF to TAF in HIV
What benefits might tenofovir alafenamide offer virologically suppressed HIV patients over tenofovir disoproxil fumarate?JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 12, 2017 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun. 12, 2017-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 12, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Approves First Generic Truvada in US FDA Approves First Generic Truvada in US
Generic versions of emtricitabine/tenofovir disoproxil, which can both treat and prevent HIV infections, are already available in other countries.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2017 Category: Consumer Health News Tags: HIV/AIDS News Alert Source Type: news

Health Highlights: June 9, 2017
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Generic Version of HIV Drug Truvada Approved by FDA The first generic version of the HIV drug Truvada (emtricitabine and tenofovir disoproxil... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 9, 2017 Category: General Medicine Source Type: news

Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women
This study provides evidence linking vaginal bacteria to microbicide efficacy through tenofovir depletion via bacterial metabolism. (Source: ScienceNOW)
Source: ScienceNOW - June 1, 2017 Category: Science Authors: Klatt, N. R., Cheu, R., Birse, K., Zevin, A. S., Perner, M., Noël-Romas, L., Grobler, A., Westmacott, G., Xie, I. Y., Butler, J., Mansoor, L., McKinnon, L. R., Passmore, J.-A. S., Abdool Karim, Q., Abdool Karim, S. S., Burgener, A. D. Tags: Medicine, Diseases r-articles Source Type: news

Gilead reports positive data from four Phase III combination trials for HIV-1
US-based biopharmaceutical firm Gilead Sciences has reported positive results from four Phase III clinical trials investigating the combination of bictegravir (BIC), emtricitabine (FTC) and tenofovir alafenamide (TAF) to treat patients with HIV-1. (Source: Drug Development Technology)
Source: Drug Development Technology - May 30, 2017 Category: Pharmaceuticals Source Type: news

Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 8, 2017 Category: Drugs & Pharmacology Source Type: news

New Tenofovir for Hep B Improves Bone and Kidney Safety (CME/CE)
(MedPage Today) -- Formulation now recommended in updated HBV treatment guidelines (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - April 24, 2017 Category: Gastroenterology Source Type: news

Viread (Tenofovir Disoproxil Fumarate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 24, 2017 Category: Drugs & Pharmacology Source Type: news

Atripla (Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 24, 2017 Category: Drugs & Pharmacology Source Type: news

Odefsey (Emtricitabine, Rilpivirine, and Tenofovir Alafenamide Fixed-dose Combination Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 20, 2017 Category: Drugs & Pharmacology Source Type: news

NHS' anti-HIV drug PrEP approved in Scotland, UK
The Scottish Medicines Consortium (SMC), UK, has approved the supply of Emtricitabine / tenofovir disoproxil (Truvada) by the National Health Service (NHS) to prevent HIV in the nation. (Source: Drug Development Technology)
Source: Drug Development Technology - April 10, 2017 Category: Pharmaceuticals Source Type: news

Vemlidy Tablets (Tenofovir Alafenamide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 10, 2017 Category: Drugs & Pharmacology Source Type: news

New Tenofovir Prodrug Is Noninferior to Currently Used Prodrug New Tenofovir Prodrug Is Noninferior to Currently Used Prodrug
Antiretroviral (ART) combinations containing the recently approved tenofovir alafenamide prodrug offer similar effectiveness and tolerability to those of combinations containing tenofovir disoproxil fumarate, according to two noninferiority trials.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 10, 2017 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Stribild (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir DF) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 10, 2017 Category: Drugs & Pharmacology Source Type: news

Tenofovir Disoproxil Fumarate Safety for Women and Infants Tenofovir Disoproxil Fumarate Safety for Women and Infants
What does available safety data tell us about preexposure prophylaxis with tenofovir disoproxil fumarate during pregnancy and lactation?AIDS (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 6, 2017 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Europe Clears Tenofovir Alafenamide (Vemlidy) for Chronic HBV Europe Clears Tenofovir Alafenamide (Vemlidy) for Chronic HBV
The efficacy of once-daily Vemlidy is similar to that of tenofovir disoproxil (Viread) with fewer bone and renal side effects, the company says.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 14, 2017 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

CDC guidelines for HIV prevention regimen may not go far enough, study suggests
A new study from the UCLA Fielding School of Public Health suggests modifying federal health guidelines related to the use of pre-exposure prophylaxis to prevent HIV transmission because current standards could miss some people who should be on it.Pre-exposure prophylaxis, or PrEP, is a measure that has proven to be highly effective in preventing HIV transmission during unprotected sex. While not entirely foolproof, studies have shown taking daily doses of tenofovir disoproxil-emtricitabine, or Truvada, is 92 percent effective in preventing HIV infection when taken correctly and consistently.Since 2012, the U.S. Centers fo...
Source: UCLA Newsroom: Health Sciences - January 7, 2017 Category: Universities & Medical Training Source Type: news

ContraVir reports positive Phase IIa trial data of tenofovir exalidex to treat Hepatitis B infection
US-based biopharmaceutical company ContraVir has reported positive data from its ongoing Phase IIa trial of tenofovir exalidex (TXL) to treat Hepatitis B infection. (Source: Drug Development Technology)
Source: Drug Development Technology - December 21, 2016 Category: Pharmaceuticals Source Type: news

Genvoya (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 20, 2016 Category: Drugs & Pharmacology Source Type: news

HIV prevention trials network launches HPTN 083
(FHI360) The HIV Prevention Trials Network (HPTN) has launched a new study, HPTN 083, to evaluate whether injectable cabotegravir (CAB) can safely protect men who have sex with men (MSM) and transgender women (TGW) who have sex with men from acquiring HIV as well as daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC). If found to be safe and effective for HIV pre-exposure prophylaxis, also known as PrEP, injectable CAB may be easier for some people to adhere to than daily oral TDF/FTC. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 20, 2016 Category: Global & Universal Source Type: news

The Success Of HIV Treatment Is Increasing The Risk Of Drug-Resistance
Global health agencies are succeeding in getting more people with HIV on antiretroviral therapy, a combination of drugs that suppress the virus to undetectable levels in the blood and reduce the risk of transmission to another person. But scientists are beginning to detect a disturbing new trend: The rise of drug-resistant HIV strains, especially in countries such as Kenya, Zambia, Uganda, Nigeria, Tanzania and South Africa.  Like tuberculosis and other diseases, drug resistant HIV strains emerge in part because a person doesn’t take the proper dose of drugs at the right time every day. In poor regions like...
Source: Science - The Huffington Post - December 6, 2016 Category: Science Source Type: news

The Success Of HIV Treatment Is Increasing The Risk Of Drug-Resistance
Global health agencies are succeeding in getting more people with HIV on antiretroviral therapy, a combination of drugs that suppress the virus to undetectable levels in the blood and reduce the risk of transmission to another person. But scientists are beginning to detect a disturbing new trend: The rise of drug-resistant HIV strains, especially in countries such as Kenya, Zambia, Uganda, Nigeria, Tanzania and South Africa.  Like tuberculosis and other diseases, drug resistant HIV strains emerge in part because a person doesn’t take the proper dose of drugs at the right time every day. In poor regions like...
Source: Healthy Living - The Huffington Post - December 6, 2016 Category: Consumer Health News Source Type: news

Tanzania: Muhimbili National Hospital Plans Free Hepatitis Treatment
[Daily News] Muhimbili National Hospital (MNH) plans to establish a diagnosis of hepatitis B virus and offer free treatment with Tenofovir medication to patients for five years effective next month. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - November 29, 2016 Category: African Health Source Type: news

Vemlidy (Tenofovir Alafenamide) for Treatment of Chronic Hepatitis B Virus Infection
Developed by Gilead Sciences, Vemlidy (Tenofovir Alafenamide) is indicated for the treatment of Hepatitis B virus infection with compensated liver disease in adult patients. (Source: Drug Development Technology)
Source: Drug Development Technology - November 24, 2016 Category: Pharmaceuticals Source Type: news

Vemlidy Tablets (Tenofovir Alafenamide) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 23, 2016 Category: Drugs & Pharmacology Source Type: news

CHMP Backs Tenofovir Alafenamide (Vemlidy) for Chronic Hep B CHMP Backs Tenofovir Alafenamide (Vemlidy) for Chronic Hep B
Vemlidy has efficacy similar to that of tenofovir disoproxil (Viread), with fewer bone and renal side effects.International Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 11, 2016 Category: Drugs & Pharmacology Tags: Infectious Diseases News Alert Source Type: news

FDA Clears Tenofovir Alafenamide (Vemlidy) for Chronic HBV FDA Clears Tenofovir Alafenamide (Vemlidy) for Chronic HBV
Once-daily Vemlidy has similar efficacy to tenofovir disoproxil (Viread) with fewer bone and renal side effects, the company says.FDA Approvals (Source: Medscape Pulmonary Medicine Headlines)
Source: Medscape Pulmonary Medicine Headlines - November 11, 2016 Category: Respiratory Medicine Tags: Gastroenterology News Source Type: news

Novel Tenofovir Drug OK'd for Hepatitis B
(MedPage Today) -- Vemlidy approved for chronic HBV infection with compensated liver disease (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 10, 2016 Category: American Health Source Type: news

FDA Approves Gilead ’s Vemlidy (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 10, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Vemlidy ® (tenofovir alafenamide, TAF) 25mg, a once-daily treatment for adults... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 10, 2016 Category: Drugs & Pharmacology Source Type: news

Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil)
This new medicine evidence summary reviewed 4 randomised trials of Truvada (emtricitabine/tenofovir disoproxil 200 mg/245 mg) for pre-exposure prophylaxis (PrEP) of HIV in either HIV-negative men or transgender women who have sex with men, or HIV-negative individuals in a heterosexual partnership with a person already infected with HIV. In these trials, Truvada reduced the relative risk of acquiring HIV infection by between 44% and 86% compared with placebo or no prophylaxis, which is equivalent to approximate numbers needed to treat of between 13 and 68 per year. In all trials, Truvada was given in addition to a comprehen...
Source: Current Awareness Service for Health (CASH) - October 6, 2016 Category: Consumer Health News Source Type: news

New Tenofovir Formulation Provides Safer Hepatitis B Treatment New Tenofovir Formulation Provides Safer Hepatitis B Treatment
A new prodrug formulation, tenofovir alafenamide, effectively treats chronic hepatitis B virus (HBV) infection with fewer bone and renal adverse effects than tenofovir disoproxil fumarate, according to two noninferiority trials.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 1, 2016 Category: Gastroenterology Tags: Infectious Diseases News Source Type: news

Emtricitabine/tenofovir alafenamide in HIV infection: Added benefit not proven
When investigators reviewed Emtricitabine/tenofovir alafenamide in HIV infection, they found that partly no data were available, and partly the appropriate comparator therapy was not adhered to. The risk of nervous system disorders was increased for one patient group, they conclude. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 18, 2016 Category: Science Source Type: news

Emtricitabine/tenofovir alafenamide in HIV infection: Added benefit not proven
(Institute for Quality and Efficiency in Health Care) Partly no data were available, partly the appropriate comparator therapy was not adhered to. The risk of nervous system disorders was increased for one patient group. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 18, 2016 Category: Global & Universal Source Type: news

Entecavir/Tenofovir Therapy in Drug Resistant Chronic HBV Entecavir/Tenofovir Therapy in Drug Resistant Chronic HBV
This study evaluated the antiviral efficacy and safety of entecavir plus tenofovir combination therapy in multidrug-resistant chronic hepatitis B patients.Liver International (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 16, 2016 Category: Infectious Diseases Tags: Infectious Diseases Journal Article Source Type: news

[In Depth] Vaginal microbiome affects HIV risk
South African teen girls and young women have astonishingly high rates of HIV infection, and researchers for years have suspected that there might be biological factors making them unusually susceptible to infection. New studies presented at the International AIDS Conference being held in Durban, South Africa—located in KwaZulu-Natal province, the hardest hit region in the country—suggest a possible culprit, Prevotella bivia, a bacterium found in the vagina that causes inflammation. The close examination of the vaginal microbiome found a second bacterium, Gardnerella, may help explain why a microbicide gel that...
Source: ScienceNOW - July 21, 2016 Category: Science Authors: Jon Cohen Tags: Infectious Disease Source Type: news

What’s keeping PrEP under wraps
PrEP, or pre-exposure prophylaxis, is a safe and effective medication that can prevent at-risk patients from contracting HIV, yet the treatment is not widely known by physicians or the patient base that could benefit most from it. Learn what HIV experts say about the treatment and the obstacles to integrating it into primary care practice. Getting the word out PrEP reaches a small proportion of the Americans who could benefit from it, experts said at an education session by the AMA LGBT Advisory Committee during the 2016 AMA Annual Meeting. “What’s really interesting about it is a lot of people haven&rsqu...
Source: AMA Wire - July 19, 2016 Category: Journals (General) Authors: Troy Parks Source Type: news